INSTITUTO-COORDENADAS
23.6.2020 18:13:05 CEST | Business Wire | Press release
In the socioeconomic recovery of Europe’s main cities following the effects of the Covid-19 pandemic, a commitment to healthcare, innovation and medical research is a key element. In that regard, Barcelona and the surrounding area play a European leadership role, uniting a powerful healthcare field with a high quality scientific research network. And according to the initial conclusions of a study by Instituto Coordenadas, the city’s response to Covid-19 is an example of public-private partnership.
The response of the healthcare sector, ensuring Barcelona is a safe city, combines with the Catalan capital’s research efforts over several decades and its strength in recruiting talent for innovation and research in biotechnology and health. The city’s hospital network, for instance, has made great strides in both medicine and research during the crisis. Some of the main achievements in that regard include the work of Hospital Clínic, and its partnership with the US-based MIT research team in particular, and the Vall d’Hebron University Hospital, which has been congratulated by the World Health Organization (WHO) for managing the fight against the pandemic. Another example of Barcelona’s dominant position lies in the work of the SciTech DiploHub, an initiative that has succeeded in bringing together the field of international scientific diplomacy.
Barcelona’s public-private scientific ecosystem has also been at work during the Covid-19 threat, with around 20 initiatives placing Catalonia’s capital at the forefront in the fight against the pandemic. Examples go from top level clinical trials, such as the one carried out by Germans Trias i Pujol Research Institute (IGTP) to stop those with the virus spreading it further, to IQS’s efforts to find an inhibitor for attacking one of the receptors of Covid-19. Most recently, the expertise of three doctors from Barcelona’s ISGlobal played a key role in redressing the errors relating to the effectiveness of hydroxychloroquine as regards Covid-19, and there is also the example of the work being carried out into new treatments for eliminating cytokine storms.
Another development that has put Barcelona on the front line has been the global partnership between the city’s six cutting-edge science centres, 110 pharmaceutical companies – with their long-standing relationship with the city – and biotech businesses and start-ups based at the Barcelona Science Park (PCB). The aim of the alliance is to secure an effective antiretroviral drug for fighting Covid-19, vaccines and more effective rapid diagnostic tests.
PCB, with its 2,800 professionals, was Spain’s first science park and is home to IRB Barcelona, which is one of the research centres selected by the European Union to identify an effective vaccine, new treatments and better rapid diagnostic tests. In fact, of the 17 projects selected in Europe, five come from Barcelona and the surrounding area.
The fight against the virus has seen the whole of the local research network entering into partnership. For instance, the Barcelona Supercomputing Center (BSC) has made its Mare Nostrum supercomputer available to researchers so they can fight the pandemic using artificial intelligence and bioinformatics.
In short, this array of alliances has put Barcelona in a position of excellence on the European map of efforts to fight Covid-19.
ABOUT INSTITUTO COORDENADAS DE GOBERNANZA Y ECONOMIA APLICADA
The institute develops thought and undertakes research into the interaction between governance and applied economics in order to make constructive and decisive progress in three fundamental issues: social wellbeing, economic progress and environmental sustainability. This takes place in a context of development and evolution, unprecedented since the end of the 18th century and the beginning of the 19th century with the industrial revolution. Faithful to its founding principles of independence, non-partisanship and plurality, the institute is a proactive leader of the fusion between the essence and innovation of economic liberalisation as the best model for tackling the challenge of the present and the future in Spain, Europe and the world.
Further information: www.institutocoordenadas.com
NOTE: The information contained in this press release is a public interest summary from reports and studies based on analysis and research; expert working groups and sessions; and/or production of scientific articles by Instituto Coordenadas de Gobernanza y Economía Aplicada. The original and complete documents are for internal use and are the sole property of Instituto Coordenadas de Gobernanza y Economía Aplicada.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 12:00:00 CEST | Press release
Powered by the Company’s breakthrough L4 and L4 Max Ouster SiliconFeatures the first patented native color lidar sensors with point for point 3D color visionIntroduces flagship OS1 Max sensor with double the range and resolution of Rev7Auto-grade, cybersecure, and designed for functional-safety Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
